Lilly’s 2009 Growth Rides On Prasugrel; Advisory Committee’s Review Is Feb. 3

 
• By Carlene Olsen

Firm reports ’08 net loss from ImClone deal and Zyprexa settlement

More from Archive

More from Pink Sheet